New Perspectives on Antimicrobial Agents: Rezafungin

Antimicrobial Agents and Chemotherapy, Journal Year: 2024, Volume and Issue: 69(1)

Published: Dec. 12, 2024

Candidemia and invasive candidiasis persist as significant causes of morbidity mortality. As fluconazole resistance rates rise, alternative means treatment are necessary, either via mold-active azoles or extended durations echinocandins. These come with the potential for undesirable side effects triazoles choosing between prolonged hospitalization outpatient parenteral antimicrobial therapy in case Rezafungin offers an opportunity to manage shorter hospital stays no access. Herein, we review most recent published data pertaining rezafungin including anti-fungal activity, pharmacokinetics, clinical relating candidiasis. Given its half-life allowing once-weekly dosing, has prophylactic agent high-risk patients, studies examine this role ongoing.

Language: Английский

---

Questioning the 14‐day dogma in candidemia treatment duration

Mycoses, Journal Year: 2023, Volume and Issue: 67(1)

Published: Oct. 28, 2023

The growing threat of antimicrobial resistance (AMR) is a global concern. With AMR directly causing 1.27 million deaths in 2019 and projections up to 10 annual by 2050, optimising infectious disease treatments imperative. Prudent use, including treatment duration, can mitigate emergence. This particularly critical candidemia, severe condition with 45% crude mortality rate, as the 14-day minimum period has not been challenged randomised comparison. A comprehensive literature search was conducted August 2023, revealing seven original articles two case series discussing durations less than 14 days for candidemia. No interventional trials or prospective observational studies assessing shorter were found. Historical showed varying candidemia durations, questioning current recommendation. Recent research observed no significant survival differences between patients receiving longer treatment, emphasising need evidence-based guidance. Treatment duration reduction post-blood culture clearance could decrease exposure antifungal drugs, limiting selection pressure, especially context emerging multiresistant Candida species. Candidemia's complexity, potential in-hospital stays underscore urgency refining strategies. Evidence-driven are imperative balance efficacy prevention ensure longevity therapies. Further clinical needed establish guidelines duration.

Language: Английский

---

ECMM Center of Excellence: A Shared Vision for the Diagnosis and Treatment of Fungal Infections

Mycopathologia, Journal Year: 2024, Volume and Issue: 189(2)

Published: March 11, 2024

Language: Английский

---

Which trial do we need? Shorter antifungal treatment for candidemia – challenging the 14-day dogma

Clinical Microbiology and Infection, Journal Year: 2024, Volume and Issue: unknown

Published: Sept. 1, 2024

Language: Английский

---